Lupin Receives Approval from U.S. FDA for Desvenlafaxine Extended-Release Tablets

0 56

Lupin Limited, a global pharmaceutical company, announced on Thursday that the US Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA), Desvenlafaxine Extended-Release Tablets, 25 mg, to bring a generic version of Pristiq Extended-Release Tablets, 25 mg of PF PRISM C.V. to market. Lupin’s factory in Goa, India, will produce the product.

In the United States, Desvenlafaxine Extended-Release Tablets, 25 mg (RLD Pristiq) had yearly sales of USD 14 million.

Contact us with your feedback and suggestions.

Leave A Reply

Your email address will not be published.